- Home
- LFT vs NMRA Comparison
LFT vs NMRA Comparison
Compare LFT & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LFT
- NMRA
- Stock Information
- Founded
- LFT 2012
- NMRA 2019
- Country
- LFT United States
- NMRA United States
- Employees
- LFT N/A
- NMRA N/A
- Industry
- LFT Real Estate Investment Trusts
- NMRA
- Sector
- LFT Real Estate
- NMRA
- Exchange
- LFT Nasdaq
- NMRA Nasdaq
- Market Cap
- LFT 125.6M
- NMRA 121.0M
- IPO Year
- LFT N/A
- NMRA 2023
- Fundamental
- Price
- LFT $2.45
- NMRA $0.77
- Analyst Decision
- LFT Hold
- NMRA Buy
- Analyst Count
- LFT 2
- NMRA 8
- Target Price
- LFT N/A
- NMRA $9.29
- AVG Volume (30 Days)
- LFT 109.3K
- NMRA 820.4K
- Earning Date
- LFT 08-11-2025
- NMRA 08-05-2025
- Dividend Yield
- LFT 16.40%
- NMRA N/A
- EPS Growth
- LFT N/A
- NMRA N/A
- EPS
- LFT 0.20
- NMRA N/A
- Revenue
- LFT $27,066,283.00
- NMRA N/A
- Revenue This Year
- LFT $152.58
- NMRA N/A
- Revenue Next Year
- LFT N/A
- NMRA N/A
- P/E Ratio
- LFT $12.36
- NMRA N/A
- Revenue Growth
- LFT N/A
- NMRA N/A
- 52 Week Low
- LFT $2.22
- NMRA $0.61
- 52 Week High
- LFT $2.84
- NMRA $17.19
- Technical
- Relative Strength Index (RSI)
- LFT 40.78
- NMRA 45.74
- Support Level
- LFT $2.45
- NMRA $0.81
- Resistance Level
- LFT $2.63
- NMRA $1.34
- Average True Range (ATR)
- LFT 0.07
- NMRA 0.10
- MACD
- LFT -0.01
- NMRA -0.01
- Stochastic Oscillator
- LFT 2.44
- NMRA 12.55
About LFT Lument Finance Trust Inc.
Lument Finance Trust Inc operates as a real estate investment trust. The company is engaged in investment, financing, and management of a portfolio of commercial real estate debt investments. It invests in transitional floating-rate commercial real estate mortgage loans, mezzanine loans, preferred equity, commercial mortgage-backed securities, fixed-rate loans, construction loans, and other CRE debt instruments.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.